IP Library Granted Patent US 10,413,572
Granted Patent B2
US 10,413,572 · App. 14/823,770 · Granted Sep 17, 2019

Liquid amnion transplant product

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,413,572
App. No.
14/823,770
Granted
Sep 17, 2019
Kind
B2
Abstract

A transplant product made from human amniotic fluid has a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color. The supernatant had been taken from the amniotic fluid which had been passed through a 170 to 260 micron blood filter, then centrifuged for 5 minutes or more at 400 g and thereafter the supernatant was separated from a pellet of debris, leaving the biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant at a temperature of −65 degrees or less prior to use and the transplant products method of use. The transplant product contains cellular material, cell fragments, proteins and growth factors maintaining the biochemical properties and is non-immunogenic while having particles up to 170 microns being passable through a 30 gauge syringe for injection.

Claims (3)

1. A liquid amnion transplant product made from human amniotic fluid comprises:

a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color, the supernatant having been taken from the amniotic fluid which had passed through a 170-260 micron blood filter wherein particles and cell fragments, some as high as 260 microns in size are in the filtered amniotic fluid, the filtered amniotic fluid being centrifuged for 5 minutes or more at 400 g wherein the supernatant is further separated from a pellet of debris particles of a size as high as 260 microns, leaving the supernatant containing cellular material or cell fragments set at a particle size so the isolated supernatant does not block a 30 gauge needle (152 microns) after being isolated and separated from the naturally occurring debris leaving biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant −65 degrees Celsius or less prior to use.

2. The liquid amnion transplant product of claim 1 wherein the supernatant further contains proteins and growth factors maintaining biochemical properties and is non-immunogenic.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Aug 29, 2022
From: BANKUNITED, N.A.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 061333/0853 →
SECURITY INTEREST Recorded Aug 4, 2022
From: VIVEX BIOLOGICS GROUP, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 061084/0607 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2019
From: HERITAGE BANK OF COMMERCE
To: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
Reel/Frame 051282/0653 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 11, 2019
From: VIVEX BIOLOGICS GROUP, INC.
To: BANKUNITED, N.A.
Reel/Frame 051260/0064 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 050079/0225 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 050079/0179 →
SECURITY INTEREST Recorded Feb 22, 2017
From: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC.; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
To: HERITAGE BANK OF COMMERCE
Reel/Frame 041782/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2017
From: NAMIN, SHABNAM; DELCROIX, GAETAN JEAN-ROBERT
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 041184/0976 →